ישראל - עברית - Ministry of Health

dexcel ltd, israel - isosorbide mononitrate - טבליה - isosorbide mononitrate 40 mg - isosorbide mononitrate - isosorbide mononitrate - for the treatment of angina pectoris and prevention of anginal attacks, treatment of congestive heart failure.

ישראל - עברית - Ministry of Health

dexcel ltd, israel - isosorbide mononitrate - טבליה - isosorbide mononitrate 20 mg - isosorbide mononitrate - isosorbide mononitrate - for the treatment of angina pectoris and prevention of anginal attacks. treatment of congestive heart failure.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - cilazapril - טבליה - cilazapril 2.5 mg - cilazapril - cilazapril - treatment of essential hypertension, renal hypertension and chronic heart failure.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - cilazapril - טבליה - cilazapril 2.5 mg - cilazapril - cilazapril - treatment of essential hypertension, renal hypertension and chronic heart failure.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - cilazapril - טבליה - cilazapril 5 mg - cilazapril - cilazapril - treatment of essential hypertension, renal hypertension and chronic heart failure.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - cilazapril - טבליה - cilazapril 5 mg - cilazapril - cilazapril - treatment of essential hypertension, renal hypertension and chronic heart failure.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - cilazapril as monohydrate; hydrochlorothiazide - טבליה - cilazapril as monohydrate 5 mg; hydrochlorothiazide 12.5 mg - cilazapril - cilazapril - treatment of essential hypertension in patients who have been stabilized on the individual components given in the same proportions.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 40 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 80 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 160 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.